NEW YORK, NY / ACCESSWIRE / July 29, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.
Community Health Systems, Inc. (NYSE: CYH)
Lawsuit on behalf of: investors who purchased February 20, 2017 - February 27, 2018
Lead Plaintiff Deadline : July 29, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/community-health-systems-inc-loss-form?prid=2644&wire=1
According to the filed complaint, during the class period, Community Health Systems, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company had understated its contractual allowances; (2) the Company had understated its provision for bad debts; (3) as a result, the Company had overstated its net operating revenue; (4) as a result, the Company had understated its net loss; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Heron Therapeutics, Inc. (NASDAQ: HRTX)
Lawsuit on behalf of: investors who purchased October 31, 2018 - April 30, 2019
Lead Plaintiff Deadline : August 5, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/heron-therapeutics-inc-loss-form?prid=2644&wire=1
According to the filed complaint, during the class period, Heron Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Heron had failed to include adequate Chemistry, Manufacturing, and Controls (“CMC”) and non-clinical information in its NDA for HTX-011; (ii) the foregoing increased the likelihood that the FDA would not approve Heron’s NDA for HTX-011; and (iii) as a result, Heron’s public statements were materially false and misleading at all relevant times.
Eros International Plc (NYSE: EROS)
Lawsuit on behalf of: investors who purchased July 28, 2017 - June 5, 2019
Lead Plaintiff Deadline : August 20, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/eros-international-plc-loss-form?prid=2644&wire=1
According to the filed complaint, during the class period, Eros International Plc made materially false and/or misleading statements and/or failed to disclose that: (1) Eros and its executives engaged in a scheme to use related-party
transactions to fabricate receivables that they reported in Eros’s public financial disclosures; (2) because of this scheme, Eros’s financial position was weaker than what the Company disclosed; (3) consequently, the Company’s Indian subsidiary, Eros International Media Ltd (“EIML”), missed loan payments and had its credit
downgraded; and (4) due to the foregoing, Defendants’ statements about Eros’s receivables, business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP